Central Serous Chorioretinopathy and Micropulse Laser Treatment

Fondazione Policlinico Universitario Agostino Gemelli IRCCS36 enrolled

Overview

To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone

Study Type

OBSERVATIONAL

Enrollment

Conditions

Central Serous Chorioretinopathy

Interventions

Subthreshold Micropulse Laser TreatmentOTHER

Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months. * Foveal serous retinal detachment for at least 6 months. * Minimum age of 18 years old at the screening time * Reading and comprehension skills of informed consent Exclusion Criteria: * Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone * No diffuse retinal epitheliopathy * Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization * Not controlled glaucoma with eyedrops, or advanced glaucoma * Myopia or hypermetropia greater than 6 diopters * Opacities of dioptric media * Low quality of optical coherence tomography (OCT) and OCT-Angiography scans * Low quality images of Fluorescein angiography and indocyanine green angiography * No written consensus signed.

Locations (1)

Fondazione Policlinico Agostino Gemelli, IRCCS

Roma, R, Italy

RECRUITING

Outcomes

Primary Outcomes

Vessel density changes

Evaluation of changes in vessel density of choriocapillaris by optical coherence tomography (OCT) angiography before and after treatment

Time frame: 12 and 24 months

Secondary Outcomes

Choroidal thickness

Evaluation of changes in choroidal thickness before and after treatment.

Time frame: 12 and 24 months

Choroidal thickness and vessel density

Correlation among changes in choroidal thickness and changes in vessel density of choriocapillary with best corrected visual acuity.

Time frame: 12 and 24 months

Qualitative analysis of retino-choroidal vascularization with identification of vascular pattern

To qualitatively evaluate the vascular patterns using optical coherence tomography (OCT) - angiography and to verify if a particular one is associated with a greater response to subthreshold micropulse laser treatment.

Time frame: 12 and 24 months

Metamorphopsia

Evaluation of quantitative improvement of metamorphosia by M-CHARTS after treatment.

Time frame: 12 and 24 months

Metamorphopsia and BCVA

Correlation between metamorphopsia and best corrected visual acuity (BCVA)

Time frame: 12 and 24 months

Ellipsoid Zone Integrity

Evaluation of ellipsoid zone integrity by optical coherence tomography (OCT) B scan.

Time frame: 12 and 24 months

Central Contacts

Maria Cristina Savastano, MD, PhD

CONTACT

(+39)063015 mariacristinasavastano@policlinicogemelli.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.